FDA underscored its interest in proposals for allowing OTC access to naloxone for treating opioid overdose by taking the unprecedented step of developing model Drug Facts labels that potential sponsors can use for their own label comprehension studies.
The agency announced the release of the model DFLs on Jan. 17 along with publication of its review of independent...